The Food and Drug Administration is warning about the risk of reactivation of hepatitis B among patients who have had that disease and who are taking some prominent and expensive newer medicines for hepatitis C.
from WSJ.com: US Business http://ift.tt/2dPmMuK
via IFTTT
No comments:
Post a Comment